Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis

Abstract

OBJECTIVE-We have developed a novel platform for display and delivery of bioactive peptides that links the biological properties of the peptide to the pharmacokinetic properties of an antibody. Peptides engineered in the MIMETIBODY platform have improved biochemical and biophysical properties that are quite distinct from those of Fc-fusion proteins. CNTO736 is a glucagon-like peptide 1 (GLP-1) receptor agonist engineered in our MIMETIBODY platform. It retains many activities of native GLP-1 yet has a significantly enhanced pharmacokinetic profile. Our goal was to develop a long-acting GLP-1 receptor agonist with sustained efficacy. RESEARCH DESIGN AND METHODS-In vitro and in vivo activity of CNTO736 was evaluated using a variety of rodent cell lines and diabetic animal models.RESULTS-Acute pharmacodynamic studies in diabetic rodents demonstrate that CNTO736 reduces fasting and postprandial glucose, decreases gastric emptying, and inhibits food intake in a GLP-1 receptor-specific manner. Reduction of food intake following CNTO736 dosing is coincident with detection of the molecule in the circumventricular organs of the brain and activation of c-fos in regions protected by the blood-brain barrier. Diabetic rodents dosed chronically with CNTO736 have lower fasting and postprandial glucose and reduced body weight. CONCLUSIONS-Takentogether, our data demonstrate that CNTO736 produces a spectrum of GLP-1 receptor-dependent actions while exhibiting significantly improved pharmacokinetics relative to the native GLP-1 peptide. Diabetes 57: [1926][1927][1928][1929][1930][1931][1932][1933][1934] 2008 D rug development strategies for therapeutic peptides continue to be challenging despite advances in technologies such as pegylation and lipidation (1-4). Although important biological processes are regulated by peptides, successful development of peptide drugs has been limited and transformation of a metabolically labile peptide into a drug remains challenging. In contrast, considerable advances have been made in the development of antibody therapeutics (5,6). A technology that could link the activity of a target peptide with the pharmacokinetic characteristics of an antibody would be a valuable addition to tools available for drug discovery. To address this need, we developed the MI-METIBODY platform as a novel technology for the display and delivery of bioactive peptides. Using protein design tools, we linked an antibody Fc domain to a bioactive glucagon-like peptide 1 (GLP-1) analog and engineered the construct for optimal biochemical and biophysical properties.GLP-1 is a 30 -amino acid peptide secreted from L-cells of the intestine following nutrient ingestion (7-10). GLP-1 is rapidly degraded in vivo with a half-life of Ͻ2 min and cleared via the kidney (11,12). When circulating glucose concentrations are elevated, GLP-1 increases insulin and decreases glucagon secretion from the pancreas and slows gastric emptying, thereby reducing glucose appearance in the circulation and enhancing glucose clearance from the circul...

GLP-2 Receptor Agonism Ameliorates Inflammation and Gastrointestinal Stasis in Murine Postoperative Ileus

“…In this study, we used the same peptide variant linked to the Fc portion of human IgG4 (GLP-2/IgG4) or mouse IgG2a (chimeric GLP-2/IgG2a). As described previously for a GLP-1 construct (Picha et al, 2008), this linkage increased half-life dramatically from minutes to days in rodents. During early evaluation of the construct for its capacity to promote mucosal growth, we observed to our surprise that the A2G GLP-2 peptide variant enhanced upper gastrointestinal transit.…”

A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects

“…PEGylation, fusion expression of bioactive peptides and human serum albumin or Fc portion of an antibody, and combination therapy of peptide drugs and protease inhibitor have been explored to prolong the half-life and improve bioavailability. [42][43][44][45] Although the fusion expression strategy may effectively extend the halflife of bioactive peptide, for maintaining high bioactivity, the bioactive peptides ought to be released in an orderly manner from the fusion protein or delivery carrier.…”

“…Sixty microliters of the sample was taken out from Eppendorf tube at appropriate intervals (0, 3,6,12,18,24,30,36,42 and 48 h). The quantity of DBAYL was measured by HPLC method at 280 nm.…”

Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture

“…Our laboratory used four structurally unique HMW GLP-1R agonists, CJC1131, CJC1134, albiglutide, and CNTO736 (20,21,27,28), to study the biology of large GLP-1R proteins. Remarkably, despite a presumed inability to rapidly and efficiently penetrate the brain, HMW GLP-1R agonists displayed the full range of actions exhibited by smaller peptide agonists, including activation of neuronal c-Fos expression, inhibition of gastric emptying, and reduction of food intake, ultimately resulting in weight loss with chronic administration.…”